PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.
Analyze analyst forecasts for the company and compare them with competitors.
124.50M
Worse than SGMO's estimated revenue of 295.73M.
-24.90M
Better than SGMO's estimated ebitda of -265.92M.
0.56
Better than SGMO's estimated eps of 0.35.
16.74M
Worse than SGMO's estimated net income of 70.59M.
-24.90M
Better than SGMO's estimated ebit of -273.37M.
4.61B
Worse than SGMO's estimated sg&a expense of 166.96M.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
-50.53%
Worse than SGMO's revenue growth rate of -3.66%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Better than SGMO's ebitda margin of -89.92%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Better than SGMO's ebit margin of -92.44%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
100.00%
Better than SGMO's cash as percentage of revenue of 83.70%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Worse than SGMO's receivables as percentage of revenue of 4.75%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Worse than SGMO's inventories as percentage of revenue of -24.48%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than SGMO's payables as percentage of revenue of 15.01%.
No Data
No DCF data available for this metric in the selected year.
-29.43%
Better than SGMO's capex as percentage of revenue of -12.81%.
4.99%
Better than SGMO's weighted average cost of capital (wacc) of 9.25%.
5.02%
Better than SGMO's cost of equity of 10.97%.
4.08%
Worse than SGMO's cost of debt of 4.06%.
-0.23
Better than SGMO's beta of 1.46.
30.07M
Better than SGMO's diluted shares outstanding of 201.70M.
1.57M
Better than SGMO's total debt of 30.57M.
49.31M
Worse than SGMO's total equity of 92.80M.
50.89M
Worse than SGMO's total capital of 123.37M.
3.09%
Better than SGMO's debt weighting of 24.78%.
96.91%
Better than SGMO's equity weighting of 75.22%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
2.00%
Equal to SGMO's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than SGMO's net debt of -11.35M.
71.33M
Better than SGMO's equity value of -586.69M.
2.37
Better than SGMO's equity value per share of -2.91.